TLD-1433 is a small molecule commercialized by Theralase Technologies, with a leading Phase II program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of TLD-1433’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for TLD-1433 is expected to reach an annual total of $17 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

TLD-1433 Overview

TLD-1433 is under development for the treatment of non-muscle invasive bladder cancer, non-small cell lung cancer and glioblastoma multiforme. The drug candidate is administered through intravesical route. It is a photodynamic therapeutic candidate. It was also under development for the treatment of oropharyngeal cancer, colon cancer and cervical cancer.

Theralase Technologies Overview

Theralase Technologies (Theralase) is a clinical stage pharmaceutical company that specializes in design, development and manufacturing of laser based technologies used in wide range of bio-destructive and bio-simulative clinical applications. It focused on the development of laser-based non-invasive therapeutic devices (laser systems) used for the reduction of chronic knee pain, inflammation, and accelerate tissue healing for numerous nerve, muscle, and joint conditions. The company photo dynamic therapy is dedicated on the discovery and development of small, light-activated photo dynamic compounds (PDC’s) and their associated drug formulations based on its proprietary non-immunosuppressive photodynamic technology targeting cancer cells, bacterial infections, and promote microbial sterilization. Theralase supplies its products through a network of distributors in Canada, the US and internationally. Theralase Technologies is headquartered in Toronto, Ontario, Canada.

The company reported revenues of (Canadian Dollars) CAD0.8 million for the fiscal year ended December 2021 (FY2021), a decrease of 15.9% over FY2020. The operating loss of the company was CAD4.4 million in FY2021, compared to an operating loss of CAD5.6 million in FY2020. The net loss of the company was CAD4.4 million in FY2021, compared to a net loss of CAD5.6 million in FY2020. The company reported revenues of CAD0.3 million for the third quarter ended September 2022, a decrease of 23.5% over the previous quarter.

For a complete picture of TLD-1433’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.